Talquetamab (tal) plus daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.

被引：0
|
作者：
Dholaria, Bhagirathbhai R.
Weisel, Katja
Mateos, Maria-Victoria
Goldschmidt, Hartmut
Martin, Thomas G.
Morillo, Daniel
Reece, Donna Ellen
Rodriguez-Otero, Paula
Bhutani, Manisha
D'Souza, Anita
Oriol, Albert
Rosinol, Laura
Bahlis, Nizar J.
Bakshi, Kalpana
Kang, Lijuan
Vandenberk, Lien
Smit, Marie-Anne Damiette
Wasch, Ralph
van de Donk, Niels W. C. J.
Chari, Ajai
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp Salamanca, Salamanca, Spain
[4] Univ Klinikum Heidelberg, Med Klin 5, Heidelberg, Germany
[5] Natl Ctr Tumorerkrankungen, Heidelberg, Germany
[6] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco Med Ctr, San Francisco, CA USA
[7] Hosp Univ Fdn Jimenez Diaz, Madrid, Spain
[8] Princess Margaret Canc Ctr, Toronto, ON, Canada
[9] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
[10] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[11] Med Coll Wisconsin, Milwaukee, WI USA
[12] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Badalona, Spain
[13] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Badalona, Spain
[14] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain
[15] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[16] Janssen Res & Dev, Spring House, PA USA
[17] Janssen Res & Dev, Antwerp, Belgium
[18] Janssen Biol Europe, Leiden, Netherlands
[19] Freiburg Univ, Med Ctr, Freiburg, Germany
[20] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands
[21] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8003
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Talquetamab plus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results
    Dholaria, Bhagirathbhai
    Weisel, Katja
    Mateos, Maria-Victoria
    Goldschmidt, Harmut
    Martin, Thomas
    Morillo, Daniel
    Reece, Donna
    Rodriguez-Otero, Paula
    Bhutani, Manisha
    D'Souza, Anita
    Oriol, Albert
    Rosinol, Laura
    Bahlis, Nizar
    Bakshi, Kalpana
    Kang, Lijuan
    Vandenberk, Lien
    Smit, M. Damiette
    Wasch, Ralph
    van de Donk, Niels
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S476 - S477
  • [2] Talquetamab (tal) plus Daratumumab (dara) plus Pomalidomide (pom) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 1b TRIMM-2 Study
    Bahlis, Nizar J.
    de Donk, Niels van
    Reece, Donna
    Bhutani, Manisha
    Dholaria, Bhagirathbhai
    D'Souza, Anita
    Martin, Thomas
    McKay, John
    Garfall, Alfred
    Krishnan, Amrita
    Bakshi, Kalpana
    Kang, Lijuan
    Vandenberk, Lien
    Prior, Thomas
    Tolbert, Jaszianne
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S1 - S1
  • [3] Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Bensinger, William
    Weisel, Katja C.
    Boyd, Kevin
    Ramasamy, Karthik
    Gonzalez, Esther
    Favre-Kontula, Linda
    Peluso, Teresa
    Sternas, Lars Axel
    Di Casoli, Carl
    Zaki, Mohamed H.
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Melflufen in patients (pts) with relapsed/refractory multiple myeloma (RRMM) refractory to daratumumab (dara) and/or pomalidomide (pom) (OP-106)
    Richardson, Paul G.
    Oriol, Albert
    Larocca, Alessandra
    Rodriguez Otero, Paula
    Moreb, Jan
    Blade, Joan
    Hassoun, Hani
    Cavo, Michele
    Alegre, Adrian
    Mazumder, Amitabha
    Maisel, Christopher
    Paner, Agne
    Leleu, Xavier
    Zonder, Jeffrey A.
    Harmenberg, Johan
    Thuresson, Sara
    Zubair, Hanan
    Mateos, Maria-Victoria
    CANCER RESEARCH, 2019, 79 (13)
  • [5] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [6] Phase 1b Results for Subcutaneous Talquetamab Plus Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma
    Chari, Ajai
    Hari, Parameswaran
    Bahlis, Nizar J.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Dholaria, Bhagirathbhai
    Garfall, Alfred L.
    Goldschmidt, Hartmut
    Kortuem, K. Martin
    Krishnan, Amrita Y.
    Martin, Thomas
    Morillo Gilles, Daniel
    Oriol, Albert
    Reece, Donna E.
    Rodriguez, Cesar
    Rodriguez-Otero, Paula
    San-Miguel, Jesus F.
    Usmani, Saad Z.
    Verona, Raluca I.
    Lin, Shun Xin Wang
    Prior, Thomas J.
    Wade, Mark
    Weiss, Brendan M.
    Goldberg, Jenna D.
    Askari, Elham
    BLOOD, 2021, 138
  • [7] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Knop, Stefan
    Lonial, Sagar
    Richardson, Paul
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, Albert
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    Van De Donk, Niels W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
  • [8] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Richardson, Paul G.
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, A.
    Knop, Stefan
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David S.
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
  • [9] Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1.
    Rodriguez-Otero, Paula
    Schinke, Carolina D.
    Chari, Ajai
    Lipe, Brea
    Lavi, Noa
    Rasche, Leo
    Vishwamitra, Deeksha
    Skerget, Sheri
    Verona, Raluca
    Ma, Xuewen
    Khedkar, Sheetal
    Hilder, Brandi
    Masterson, Tara J.
    Campagna, Michela
    Renaud, Thomas
    Tolbert, Jaszianne A.
    Heuck, Christoph
    Smit, Marie-Anne Damiette
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Talquetamab (tal) plus Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-Up
    Cohen, Yael
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique
    Yoon, Sung-Soo
    Chu, Michael
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia
    Krevvata, Maria
    Peterson, Michelle
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S2 - S3
12345